Effects of Intranasal Oxytocin in Patients With Central Diabetes Insipidus
Status:
Not yet recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose
intranasal oxytocin (4 IU and 24 IU) in 18-60-year-old men and women with central diabetes
insipidus to evaluate the effect of oxytocin on anxiety, depression and socioemotional
functioning.
Following a screening visit to determine eligibility, participants will return for three main
study visits. During the main study visits, study participants will receive either oxytocin
or placebo, followed by assessments of emotional behavior.
Thirty participants will be equally randomized to one of six possible drug orders:
1. 4 IU oxytocin - 24 IU oxytocin - placebo
2. 4 IU oxytocin - placebo - 24 IU oxytocin
3. 24 IU oxytocin - 4 IU oxytocin - placebo
4. 24 IU oxytocin - placebo - 4 IU oxytocin
5. placebo - 4 IU oxytocin - 24 IU oxytocin
6. placebo - 24 IU oxytocin - 4 IU oxytocin